You are here

Annexon

Annexon reports topline results from Phase II trial of geographic atrophy therapy

Annexon reports topline results from Phase II trial of geographic atrophy therapy

Clinical Trials Arena

clinical trials

geographic atrophy

Flag link:

This week's wave of biotech IPO players bumps up offerings and targets bigger harvests of cash

This week's wave of biotech IPO players bumps up offerings and targets bigger harvests of cash

Endpoints

Nurix Therapeutics

Flag link:

FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome

FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome

Pharmaceutical Business Review

Guillain-Barré Syndrome

Flag link:

Annexon Biosciences Closes $75 Million Series C Round

Annexon Biosciences Closes $75 Million Series C Round

CP Wire

Flag link:

Annexon Biosciences Closes $75 Million Series C Round

Flag link:

Novartis quarterbacks a $34M round for Huntington's startup Annexon

Novartis quarterbacks a $34M round for Huntington's startup Annexon

Fierce Biotech

Huntington's disease

Flag link: